AstraZeneca Signs $555 Million AI Drug Discovery Deal with Algen Biotechnologies
Summary
AstraZeneca strikes a massive $555 million partnership with Algen Biotechnologies, combining cutting-edge AI platform 'AlgenBrain' with CRISPR gene technology to revolutionize drug discovery for chronic inflammatory diseases and unlock next-generation immunology therapies.
Key Points
- AstraZeneca signs a $555 million deal with San Francisco-based Algen Biotechnologies to use AI platform 'AlgenBrain' for discovering new immunology targets
- The partnership combines advanced CRISPR gene modulation with AI-driven drug discovery to develop next-generation therapies for chronic inflammatory conditions
- AstraZeneca gains exclusive rights to develop and commercialize therapies from targets identified through the collaboration, while Algen receives upfront payment plus milestone payments totaling up to $555 million